Table 3 RAD21 expression in invasive carcinoma by clinicopathological parameters
| Â | negative n (%) | positive n (%) | Total n (%) | P value |
|---|---|---|---|---|
Grade | Â | Â | Â | P = 0.328 |
   1 | 42 (17.6%) | 16 (15.4%) | 58 (16.9%) |  |
   2 | 96 (40.2%) | 35 (33.7%) | 131 (38.2%) |  |
   3 | 101 (42.3%) | 53 (51.0%) | 154 (44.9%) |  |
Size | Â | Â | Â | P = 0.012 |
   <20 mm | 147 (61.8%) | 50 (47.2) | 197 (57.3%) |  |
   >20 mm | 91 (38.2%) | 56 (52.8%) | 147 (42.7) |  |
Lymph node | Â | Â | Â | P < 0.001 |
   Negative | 148 (63.5%) | 43 (42.2%) | 191 (57.0%) |  |
   Positive | 85 (36.5%) | 59 (57.8%) | 144 (43.0%) |  |
Age | Â | Â | Â | P = 0.815 |
   <50 | 84 (35.1%) | 39 (36.4%) | 123 (35.5%) |  |
   >50 | 155 (64.9) | 68 (63.6%) | 223 (64.5%) |  |
ER | Â | Â | Â | P = 0.054 |
   Negative | 63 (34.4%) | 14 (21.5%) | 77 (31/0%) |  |
   Positive | 120 (65.6%) | 51 (78.5%) | 171 (69.0%) |  |
HER2 | Â | Â | Â | P = 0.564 |
   Negative | 142 (79.8%) | 54 (83.1%) | 196 (80.7%) |  |
   Positive | 36 (20.2%) | 11 (16.9%) | 47 (19.3%) |  |
Chemotherapy* | Â | Â | Â | P = 0.032 |
   No | 117 (62.95) | 31 (47.7%) | 148 (59.0%) |  |
   Yes | 69 (37.1%) | 34 (52.3%) | 103 (41.0%) |  |
Endocrine therapy | Â | Â | Â | P = 0.034 |
   No | 97 (52.2%) | 24 (36.9%) | 121 (48.2%) |  |
   Yes | 89 (47.8%) | 41 (63.1%) | 130 (51.8%) |  |